KR20010013887A - 건강한 사람의 감정 장애 조절을 위한 조성물 - Google Patents
건강한 사람의 감정 장애 조절을 위한 조성물 Download PDFInfo
- Publication number
- KR20010013887A KR20010013887A KR1019997011909A KR19997011909A KR20010013887A KR 20010013887 A KR20010013887 A KR 20010013887A KR 1019997011909 A KR1019997011909 A KR 1019997011909A KR 19997011909 A KR19997011909 A KR 19997011909A KR 20010013887 A KR20010013887 A KR 20010013887A
- Authority
- KR
- South Korea
- Prior art keywords
- acetyl
- carnitine
- acid
- pharmacologically acceptable
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 208000019022 Mood disease Diseases 0.000 title description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 208000027534 Emotional disease Diseases 0.000 claims abstract description 15
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims description 18
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims description 6
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims description 5
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims description 5
- 206010026749 Mania Diseases 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 230000003542 behavioural effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000002858 neurotransmitter agent Substances 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- JATPLOXBFFRHDN-DDWIOCJRSA-N [(2r)-2-acetyloxy-3-carboxypropyl]-trimethylazanium;chloride Chemical compound [Cl-].CC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C JATPLOXBFFRHDN-DDWIOCJRSA-N 0.000 claims 1
- 210000001217 buttock Anatomy 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 235000012976 tarts Nutrition 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- 230000002996 emotional effect Effects 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012332 laboratory investigation Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- -1 notlipritin Chemical compound 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Percussion Or Vibration Massage (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97RM000365A IT1291930B1 (it) | 1997-06-18 | 1997-06-18 | Composizione riequilibratrice delle turbe dell'umore in individui sani |
| ITRM97A000365 | 1997-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010013887A true KR20010013887A (ko) | 2001-02-26 |
Family
ID=11405131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019997011909A Withdrawn KR20010013887A (ko) | 1997-06-18 | 1998-06-12 | 건강한 사람의 감정 장애 조절을 위한 조성물 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6335021B1 (https=) |
| EP (1) | EP1001760B1 (https=) |
| JP (1) | JP2002505681A (https=) |
| KR (1) | KR20010013887A (https=) |
| AT (1) | ATE288265T1 (https=) |
| AU (1) | AU7930498A (https=) |
| CA (1) | CA2294589A1 (https=) |
| DE (1) | DE69828881T2 (https=) |
| DK (1) | DK1001760T3 (https=) |
| ES (1) | ES2236910T3 (https=) |
| IT (1) | IT1291930B1 (https=) |
| PT (1) | PT1001760E (https=) |
| WO (1) | WO1998057629A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2806307B1 (fr) * | 2000-03-20 | 2002-11-15 | Mane Fils V | Preparation parfumee solide sous forme de microbilles et utilisation de ladite preparation |
| JP4387105B2 (ja) * | 2001-03-04 | 2009-12-16 | アイシーユー・メディカル・インコーポレーテッド | インフュージョンハブアセンブリおよび流体ライン切断システム |
| PL367628A1 (en) * | 2001-05-29 | 2005-03-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia |
| US20050272812A1 (en) * | 2002-02-07 | 2005-12-08 | Pettegrew Jay W | Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans |
| US7407778B2 (en) * | 2002-02-07 | 2008-08-05 | Pettegrew Jay W | Compounds, compositions and methods for treating neuropsychiatric disorders |
| US7700074B2 (en) * | 2002-02-07 | 2010-04-20 | Pettegrew Jay W | Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism |
| US20040071681A1 (en) * | 2002-10-10 | 2004-04-15 | Lydia Muller | Method and composition for reducing cravings for a craved substance |
| US7815894B2 (en) * | 2003-05-29 | 2010-10-19 | Jay W. Pettegrew | Compounds, compositions and methods for medical imaging of neuropsychiatric disorders |
| US20060257842A1 (en) * | 2003-05-29 | 2006-11-16 | Pettegrew Jay W | Cryopreservation media and molecules |
| US8173618B2 (en) * | 2003-07-25 | 2012-05-08 | University Of Massachusetts | Formulations for reducing neuronal degeneration |
| JP2006137746A (ja) * | 2004-10-13 | 2006-06-01 | Otsuka Pharmaceut Factory Inc | オレキシン誘導組成物 |
| US20070015518A1 (en) * | 2005-07-15 | 2007-01-18 | Agilis Systems, Inc. | Mobile resource location-based customer contact systems |
| US20070124219A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized nutraceutical selection and packaging |
| US20080114577A1 (en) * | 2005-11-30 | 2008-05-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems associated with nutraceutical related assays |
| US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
| US20080033763A1 (en) * | 2005-11-30 | 2008-02-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems related to receiving nutraceutical associated information |
| US20110145009A1 (en) * | 2005-11-30 | 2011-06-16 | Jung Edward K Y | Methods and systems related to transmission of nutraceutical associatd information |
| US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
| US20080103746A1 (en) * | 2005-11-30 | 2008-05-01 | Searete Llc, A Limited Liability Corporation | Systems and methods for pathogen detection and response |
| US20070136092A1 (en) * | 2005-11-30 | 2007-06-14 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
| US20070289258A1 (en) * | 2006-06-14 | 2007-12-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Individualized pharmaceutical selection and packaging |
| US8340944B2 (en) * | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US7827042B2 (en) * | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
| US7927787B2 (en) * | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
| US10296720B2 (en) * | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
| US20070124176A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US20080052114A1 (en) * | 2005-11-30 | 2008-02-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods related to nutraceuticals |
| US20080004905A1 (en) * | 2006-06-28 | 2008-01-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for analysis of nutraceutical associated components |
| US8597640B2 (en) * | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
| MX2012014127A (es) | 2010-06-16 | 2013-06-28 | Sigma Tau Ind Farmaceuti | Acetil-carnitina para uso en un metodo para incrementar neurogenesis en tejido nervioso. |
| KR20230011999A (ko) | 2020-05-15 | 2023-01-25 | 알파시그마 에스.피.에이. | 메틸폴레이트를 포함하는 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0340759A1 (en) | 1988-05-06 | 1989-11-08 | MAGIS FARMACEUTICI S.p.A. | Salts of O-mono (di)-acetyl-glycero-mono-(bis)-(di)-phosphates of L-acetyl-carnitine and of L-acetyl carnitine esters |
| JP3942207B2 (ja) * | 1995-02-17 | 2007-07-11 | 武田薬品工業株式会社 | うつ性症状改善剤 |
| US5977162A (en) * | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
| US6066664A (en) * | 1997-06-06 | 2000-05-23 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Method for decreasing the appetite in bulimic, overweight individuals |
-
1997
- 1997-06-18 IT IT97RM000365A patent/IT1291930B1/it active IP Right Grant
-
1998
- 1998-06-12 JP JP50409799A patent/JP2002505681A/ja active Pending
- 1998-06-12 EP EP98929625A patent/EP1001760B1/en not_active Expired - Lifetime
- 1998-06-12 PT PT98929625T patent/PT1001760E/pt unknown
- 1998-06-12 DK DK98929625T patent/DK1001760T3/da active
- 1998-06-12 WO PCT/IT1998/000157 patent/WO1998057629A1/en not_active Ceased
- 1998-06-12 ES ES98929625T patent/ES2236910T3/es not_active Expired - Lifetime
- 1998-06-12 AU AU79304/98A patent/AU7930498A/en not_active Abandoned
- 1998-06-12 AT AT98929625T patent/ATE288265T1/de not_active IP Right Cessation
- 1998-06-12 CA CA002294589A patent/CA2294589A1/en not_active Abandoned
- 1998-06-12 KR KR1019997011909A patent/KR20010013887A/ko not_active Withdrawn
- 1998-06-12 DE DE69828881T patent/DE69828881T2/de not_active Expired - Fee Related
- 1998-06-12 US US09/446,358 patent/US6335021B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ITRM970365A0 (https=) | 1997-06-18 |
| DK1001760T3 (da) | 2005-05-23 |
| WO1998057629A1 (en) | 1998-12-23 |
| EP1001760A1 (en) | 2000-05-24 |
| ITRM970365A1 (it) | 1998-12-18 |
| DE69828881D1 (de) | 2005-03-10 |
| AU7930498A (en) | 1999-01-04 |
| PT1001760E (pt) | 2005-04-29 |
| JP2002505681A (ja) | 2002-02-19 |
| ES2236910T3 (es) | 2005-07-16 |
| ATE288265T1 (de) | 2005-02-15 |
| DE69828881T2 (de) | 2006-01-19 |
| EP1001760B1 (en) | 2005-02-02 |
| IT1291930B1 (it) | 1999-01-21 |
| US6335021B1 (en) | 2002-01-01 |
| CA2294589A1 (en) | 1998-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20010013887A (ko) | 건강한 사람의 감정 장애 조절을 위한 조성물 | |
| US4507323A (en) | Treatment of psychosexual dysfunctions | |
| US7834056B2 (en) | Pharmaceutical composition for gout | |
| MXPA05002827A (es) | Formulaciones farmaceuticas de modafinil. | |
| US4435449A (en) | Treatment of minimal brain dysfunction (MBD) | |
| IE893690L (en) | Treatment of obesity | |
| CZ295567B6 (cs) | Tetrahydrolipstatin pro výrobu orálního farmaceutického prostředku pro ošetřování typu II diabetes mellitus | |
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| WO2007046347A1 (ja) | 筋萎縮性側索硬化症患者の運動神経保護用医薬 | |
| JP4276779B2 (ja) | 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用 | |
| JP2001518481A (ja) | 経口投与のためのセロトニン含有製剤及びその使用方法 | |
| CN114555070A (zh) | 月经周期诱发的症状治疗 | |
| Knezevic et al. | Neuroleptic malignant syndrome | |
| JP3455633B2 (ja) | 潰瘍性大腸炎の予防又は治療剤 | |
| HU229214B1 (hu) | Propionil-L-karnitint és további hatóanyagokat tartalmazó kombinációs készítmény alkalmazása merevedési zavar kezelésére | |
| JPH04342528A (ja) | アルコール代謝およびアセトアルデヒド代謝促進剤 | |
| JP2000186040A (ja) | 抗ｈｉｖ感染症剤 | |
| Parkes | Clinical pharmacology of amantadine and derivatives | |
| KR20210097487A (ko) | 후코이단을 포함하는 수면장애 예방, 개선 또는 치료용 조성물 | |
| RU2404976C1 (ru) | Средство, снижающее влечение к алкоголизму, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения | |
| US6946452B2 (en) | Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for treating motion sickness | |
| MXPA99011750A (en) | Composition for controlling mood disorders in healthy individuals | |
| US4552865A (en) | Psychotropic drugs | |
| JP2014065694A (ja) | アスパラギン酸を含有する睡眠改善剤 | |
| JP2014162761A (ja) | 血中ａｐｏＣＩ濃度低下剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19991216 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |